112 related articles for article (PubMed ID: 19931343)
1. Treatment of human respiratory syncytial virus infected Balb/C mice with the proteasome inhibitor bortezomib (Velcade, PS-341) results in increased inflammation and mortality.
Lupfer C; Patton KM; Pastey MK
Toxicology; 2010 Jan; 268(1-2):25-30. PubMed ID: 19931343
[TBL] [Abstract][Full Text] [Related]
2. Primary infection of mice with high titer inoculum respiratory syncytial virus: characterization and response to antiviral therapy.
Bolger G; Lapeyre N; Dansereau N; Lagacé L; Berry G; Klosowski K; Mewhort T; Liuzzi M
Can J Physiol Pharmacol; 2005 Feb; 83(2):198-213. PubMed ID: 15791294
[TBL] [Abstract][Full Text] [Related]
3. The proteasome inhibitor bortezomib enhances the susceptibility to viral infection.
Basler M; Lauer C; Beck U; Groettrup M
J Immunol; 2009 Nov; 183(10):6145-50. PubMed ID: 19841190
[TBL] [Abstract][Full Text] [Related]
4. Effects of norakin on respiratory syncytial virus in tissue culture and in mice.
Mentel R; Schroeder C; Döhner L
Acta Virol; 1989 Mar; 33(2):162-6. PubMed ID: 2569812
[TBL] [Abstract][Full Text] [Related]
5. [In vitro inhibitory mechanism of respiratory syncytial virus with solution prescription of zhidanhuayu].
Liu YH; Hou AC; Zhao GC
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2008 Dec; 22(6):486-7. PubMed ID: 19544654
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of respiratory syncytial virus of subgroups A and B using deoxyribozyme DZ1133 in mice.
Zhou J; Yang XQ; Xie YY; Zhao XD; Jiang LP; Wang LJ; Cui YX
Virus Res; 2007 Dec; 130(1-2):241-8. PubMed ID: 17804108
[TBL] [Abstract][Full Text] [Related]
7. Proteasome inhibition as a novel therapeutic target in human cancer.
Rajkumar SV; Richardson PG; Hideshima T; Anderson KC
J Clin Oncol; 2005 Jan; 23(3):630-9. PubMed ID: 15659509
[TBL] [Abstract][Full Text] [Related]
8. Proteasome inhibition for treatment of multiple myeloma: clinical update.
Stadtmauer EA
J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S10-5. PubMed ID: 19795531
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib-mediated proteasome inhibition as a potential strategy for the treatment of rhabdomyosarcoma.
Bersani F; Taulli R; Accornero P; Morotti A; Miretti S; Crepaldi T; Ponzetto C
Eur J Cancer; 2008 Apr; 44(6):876-84. PubMed ID: 18342500
[TBL] [Abstract][Full Text] [Related]
10. An immunocompromised BALB/c mouse model for respiratory syncytial virus infection.
Kong X; Hellermann GR; Patton G; Kumar M; Behera A; Randall TS; Zhang J; Lockey RF; Mohapatra SS
Virol J; 2005 Feb; 2():3. PubMed ID: 15701174
[TBL] [Abstract][Full Text] [Related]
11. Contribution of the respiratory syncytial virus G glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo.
Teng MN; Whitehead SS; Collins PL
Virology; 2001 Oct; 289(2):283-96. PubMed ID: 11689051
[TBL] [Abstract][Full Text] [Related]
12. Proteasome inhibition attenuates hepatic injury in the bile duct-ligated mouse.
Anan A; Baskin-Bey ES; Isomoto H; Mott JL; Bronk SF; Albrecht JH; Gores GJ
Am J Physiol Gastrointest Liver Physiol; 2006 Oct; 291(4):G709-16. PubMed ID: 16798723
[TBL] [Abstract][Full Text] [Related]
13. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.
Ludwig H; Khayat D; Giaccone G; Facon T
Cancer; 2005 Nov; 104(9):1794-807. PubMed ID: 16178003
[TBL] [Abstract][Full Text] [Related]
14. DSCG reduces RSV-induced illness in RSV-infected mice.
Hashimoto K; Mori S; Hashimoto Y; Kaneko H; Ishibashi K; Ishioka K; Kawasaki Y; Peebles RS; Munakata M; Hosoya M; Suzutani T
J Med Virol; 2009 Feb; 81(2):354-61. PubMed ID: 19107959
[TBL] [Abstract][Full Text] [Related]
15. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells.
Nawrocki ST; Carew JS; Pino MS; Highshaw RA; Andtbacka RH; Dunner K; Pal A; Bornmann WG; Chiao PJ; Huang P; Xiong H; Abbruzzese JL; McConkey DJ
Cancer Res; 2006 Apr; 66(7):3773-81. PubMed ID: 16585204
[TBL] [Abstract][Full Text] [Related]
16. RNA interference inhibits respiratory syncytial virus replication and disease pathogenesis without inhibiting priming of the memory immune response.
Zhang W; Tripp RA
J Virol; 2008 Dec; 82(24):12221-31. PubMed ID: 18818323
[TBL] [Abstract][Full Text] [Related]
17. Expression of interleukin-4 by recombinant respiratory syncytial virus is associated with accelerated inflammation and a nonfunctional cytotoxic T-lymphocyte response following primary infection but not following challenge with wild-type virus.
Bukreyev A; Belyakov IM; Prince GA; Yim KC; Harris KK; Berzofsky JA; Collins PL
J Virol; 2005 Aug; 79(15):9515-26. PubMed ID: 16014914
[TBL] [Abstract][Full Text] [Related]
18. Proteasome inhibition drastically but reversibly impairs murine lymphocyte development.
Maseda D; Meister S; Neubert K; Herrmann M; Voll RE
Cell Death Differ; 2008 Mar; 15(3):600-12. PubMed ID: 18188168
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib in multiple myeloma.
Mateos MV; San Miguel JF
Best Pract Res Clin Haematol; 2007 Dec; 20(4):701-15. PubMed ID: 18070714
[TBL] [Abstract][Full Text] [Related]
20. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
